TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Galectin-9 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients discharged 'early'
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: All-cause rehospitalisation
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline in ESSDAI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygenation Index on Day 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Conversational Turn Count percentile score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adult Word Count percentile score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 4 m gait speed test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life in sarcopenia scale (SARQoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Oswestory Disability Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Pyrotinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve from Time Zero to Last Measurable Concentration (AUC0-t) of Pyrotinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity (AUC0-Inf) of Pyrotinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of solicited local reactogenicity adverse events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Grade of solicited local reactogenicity adverse events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of solicited systemic reactogenicity adverse events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Grade of solicited systemic reactogenicity adverse events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Food choice
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage time of co-contractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Non-Suicidal Self Injury Behaviors at 30 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved Reports of Social Isolation and Loneliness
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Improved Results from Participant's Typical Treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Isometric elbow extension/flexion force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cutaneous Irritancy Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: SpO2 changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Digital Game Addiction Awareness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinicians diagnosis of axSpA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hemoglobin (Hb) level improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Variability of plethysmography curve depending on the respiratory rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Variability of plethysmography curve depending on the tidal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Unfavorable Neurologic Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Urinary BPA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Stent dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: modified Thrombolysis in Cerebral Infarction scale (mTICI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Difference in total WOMAC score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rate of AESI
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Liver transplant
Endpoint domain: Mortality/survival
Primary endpoint: Need for local anesthetic supplementation
Endpoint domain: Adverse events/effects
Primary endpoint: HPV Vaccine Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: HPV Vaccine Awareness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: HPV Vaccine Attitude
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Statistical learning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Retention of statistical learning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in mitral valve velocity time-integral (cm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline in hematology parameter platelets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from Baseline in alanine aminotransferase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Physical discomfort related to the intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Determining FAST efficacy in reducing hip impact force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients able to initiate the AR game and activate targets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of eyes achieving uncorrected visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eating assessment score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ureteral visibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time required to identify ureter
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total analgesic requisite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of post-traumatic stress disorder (PTSD)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Theta-Gamma Coupling After Sham iTBS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Theta-Gamma Coupling after Active iTBS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of hematologic malignancies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Frequency, grade, and relationship of SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Stroke metrics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ibuprofen Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants declaring no medical care at risk of concussion
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Medication Adherence (coverage rate)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Investigator Tolerability Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Subject Tolerability Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Dry Eye-Related Quality-Of-Life Score (DEQS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 30-day unplanned hospital visit rate
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: oral care behavior
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Number of Participants With Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Serious AEs (SAEs), AEs of Special Interest (AESIs), and AEs Leading to Study Withdrawal or Discontinuation of Study Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Medically Attended Adverse Events (MAAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in New York Heart Association (NYHA) Classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in six-minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Kansas City Cardiomyopathy Questionnaire Overall Score (KCCQ-OS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Score on Critical-Care Pain Assessment Tool (CPOT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score on Visual Analog Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac uptake of 18F-FDG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Brief Negative Symptoms Scale - apathy subscale (BNSS-Apathy)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Extended Glasgow Outcome Scale (GOS-E)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pharmacokinetics of oxytocin in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Self-reported impact of using POCT device
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Score at Female Sexual Function Index scale (DSDI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Score at World Health Organization quality of life assessment - bref scale (WHOQOL-Bref)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Score at Mini-Mental State Examination scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time of functional ductus arteriosus closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of culture-confirmed VVC recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Clinical Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Clinical Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in papillodema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement of headache
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Expected Body Weight Percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Impairment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in plasma AgRP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Correlation of Plasma AgRP levels with IGF-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Behavioral Assessment System Child Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Alabama Parenting Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Parent Locus of Control
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of FAPI SUV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accessibility sonar guided
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: number of punctures needed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Subjects free from failure
Endpoint domain: Mortality/survival
Primary endpoint: Montgomery-Asberg Depression Rating Scale (MADRS) at 3 Months
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time in therapeutic INR range (TTR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of patients transitioned to patient self-management
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Change from Baseline in Neutrophil Extracellular Traps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from Baseline in Damage-associated Molecular Pattern Molecules
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of women with prolonged labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Satisfaction of Labor
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: best amplitude of nerve conduction study
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Care Needs
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Disaster Literacy Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: General Disaster Preparedness Belief Scale Using the Health Belief
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in measurement-based care frequency
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Postoperative moderate-to-severe pulmonary complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Infection rates related to fractures and trauma
Endpoint domain: Adverse events/effects
Primary endpoint: Variation in arterial lactate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: per-patient sensitivity and specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute stress effects on subjective experience
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HPA response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: liver progression-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Defending Behavior in bullying incidents
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Cyberbullying Perpetration
Endpoint domain: Adverse events/effects
Primary endpoint: School bullying perpetration and victimization
Endpoint domain: Adverse events/effects
Primary endpoint: Attachment Security
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Infant Socio-Emotional Development
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Duration of Daily App Use
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Frequency of App Use as Measured by Interactions Per Day
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: App Usability as Measured by the Systems Usability Scale
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Near high-contrast visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conditioned pain modulation (CPM) effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endogenous pain modulation (EPM) efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: real-world progression-free survival
Endpoint domain: Mortality/survival
Primary endpoint: real world time to next treatment (rwTTNT)
Endpoint domain: Mortality/survival
Primary endpoint: real world intracranial progression free survival (rwICPFS)
Endpoint domain: Mortality/survival
Primary endpoint: Tic symptoms severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emotional and Behavioral functioning
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 90-day wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WHOQOL-BREFF
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of surgery-free patients post-treatment
Endpoint domain: Mortality/survival
Primary endpoint: Ratio of average Activity Duration (RAAD)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Intrinsic Motivation Inventory Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quebec User Evaluation of Satisfaction with assistive Technology score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Participants With Parasitaemia Below Limit of Quantification (LOQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Area Under the Concentration-time Curve Over the Dosing Interval from Time 0 to 24 hours (AUCτ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum (peak) Observed Plasma Drug Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Observed Drug Concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants achieving SVR-12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Subject's Response to Tolerability Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety Assessment Through Collection of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Persisting on Treatment With Vedolizumab IV Compared to Participants With Treatment Change up to 12 Months
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total sleep time during exposure to nocturnal tyre noise combination A1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total sleep time during exposure to nocturnal tyre noise combination A2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total sleep time during exposure to nocturnal tyre noise combination B1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Anatomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carotid End-Diastolic Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Motor performance score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Instantaneous motor performance score (iMPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of melatonin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes of cortisol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pressure-Pain Threshold-Algometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Architecture and Hypertrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: GOALS scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: OSA-LS scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Free from fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balloon pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of Implementation Strategies
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of Implementation Strategies
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Appropriateness of Implementation Strategies
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Nicotine Cmax0-120
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urge to Smoke - Defined use
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Kinematics of the Lumbar Spine and Hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first request of rescue postoperative analgesic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of men who are eligible
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Length of time needed to enroll 15 men
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Facilitator-assessed attendance in intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cut-off Perfusion Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of weeks worked
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Pain level during wound treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of TCUS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fear rating
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of all-cause sick visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of participants with mild symptoms of early pertussis disease postchallenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of usable images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes